Benzinga | Jan 29, 2021 09:39AM EST

SVB Leerink Maintains Market Perform on Abiomed, Raises Price Target to $375

SVB Leerink analyst Danielle Antalffy maintains Abiomed (NASDAQ:ABMD) with a Market Perform and raises the price target from $320 to $375.